Analysts anticipate Valeant to post $2.1B in quarterly sales — 4 insights

Zacks Investment Research believes Valeant Pharmaceuticals will post $2.17 billion in sales for the current financial quarter, Stock News Times reports.

Here's what you should know:

1. Five analyst firms made predictions on Valeant's quarterly sales, the lowest estimate was $2.09 billion, while the highest was $2.24 billion.

2. If the estimates are correct, it shows Valeant sales decreased 9.6 percent year over year.

3. Valeant will announce its quarterly earnings Feb. 27.

4. Analysts anticipate full-year sales between $8.65 billion to $8.80 billion.

More articles on supply chain:  
Campbell Clinic receives 8-year tax abatement for $30M expansion with ASC — 4 insights
Maximize your 2018 reimbursements: Know your health plans, know your market, and stay on top of trends
21 statistics on ASC accounts receivable

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months